Deciphera Pharmaceuticals, LLC is a commercial-stage biopharmaceutical company headquartered in Waltham, Massachusetts, with research facilities in Lawrence, Kansas. A wholly owned subsidiary of Ono Pharmaceutical Co., Ltd. since 2024, it focuses on discovering, developing, and commercializing kinase inhibitor medicines, primarily for cancer patients.
Leveraging its proprietary switch-control kinase inhibitor platform, Deciphera targets oncology, neurology, and immunology indications with high unmet needs. Key approved products include QINLOCK (ripretinib), a treatment for advanced gastrointestinal stromal tumor (GIST) in patients previously treated with three or more kinase inhibitors, approved in the US and EU; and ROMVIMZA (vimseltinib), for symptomatic tenosynovial giant cell tumor (TGCT) where surgery is not viable, approved in the US and EU.
The company maintains a pipeline of candidates such as tirabrutinib for relapsed/refractory primary central nervous system lymphoma and others addressing GIST, polycythemia vera, and more. Founded in 2003, Deciphera operates commercial platforms in the US and Europe.
To provide comprehensive coverage, we aggregate data and news under the name Deciphera, encompassing the following company names, divisions, and related entities:
Deciphera Pharmaceuticals, Inc..
This list encompasses current and former names, alternate names, and key divisions associated with Deciphera, ensuring you can easily find all relevant information under a single, unified profile.
